Quarterly report [Sections 13 or 15(d)]

Shareholders' Equity - Additional Information (Details)

Shareholders' Equity - Additional Information (Details)																	1 Months Ended	3 Months Ended	9 Months Ended		14 Months Ended	48 Months Ended	56 Months Ended	63 Months Ended
Shareholders' Equity - Additional Information (Details)	Sep. 30, 2025 USD ($) $ / shares shares	Apr. 28, 2025 USD ($) $ / shares shares	Feb. 19, 2025 USD ($)	Jan. 31, 2025 USD ($) shares	Dec. 10, 2024 USD ($)	Aug. 09, 2024 USD ($) $ / shares shares	Oct. 07, 2022 USD ($) $ / shares	Feb. 12, 2021 $ / shares shares	Feb. 10, 2021 $ / shares shares	Feb. 08, 2021 $ / shares shares	Oct. 31, 2020 $ / shares shares	Oct. 27, 2020 $ / shares shares	Jul. 02, 2020 $ / shares shares	Jun. 05, 2020 $ / shares shares	Jun. 03, 2020 $ / shares shares	Apr. 27, 2018 USD ($) $ / shares shares	Jun. 30, 2020 $ / shares shares	Sep. 30, 2025 USD ($) $ / shares shares	Sep. 30, 2025 USD ($) Vote $ / shares shares	Sep. 30, 2024 USD ($)	Sep. 30, 2025 USD ($) $ / shares shares	Jan. 31, 2025 USD ($) shares	Sep. 30, 2025 USD ($) $ / shares shares	Sep. 30, 2025 USD ($) $ / shares shares	Jun. 29, 2025 shares	Dec. 31, 2024 USD ($) $ / shares shares	May 03, 2023 $ / shares shares
Class Of Stock [Line Items]
Increase to authorized ordinary shares																											60,000,000
Ordinary shares, par value \| $ / shares	$ 0.01																	$ 0.01	$ 0.01		$ 0.01		$ 0.01	$ 0.01		$ 0.01	$ 0.01
Aggregate offering price of shares \| $	$ 490,000																	$ 490,000	$ 490,000		$ 490,000		$ 490,000	$ 490,000		$ 315,000
Ordinary shares, shares authorized	80,000,000																	80,000,000	80,000,000		80,000,000		80,000,000	80,000,000		80,000,000
Number of vote per common share \| Vote																			1
Common stock rights and preferences																			There are no redemption or sinking fund provisions with respect to the authorized ordinary shares.
Authorized amount for sale of stock \| $			$ 150,000,000
Ordinary shares, shares issued	48,991,860	3,040,000																48,991,860	48,991,860		48,991,860		48,991,860	48,991,860		31,534,233
Price per ordinary share \| $ / shares		$ 0.9
Prefunded warrants to purchase shares of common stock		2,515,556
Prefunded warrant issued per share \| $ / shares		$ 0.89
Net proceeds from issuance of common stock \| $		$ 4,177,000
Aggregate gross proceeds from ordinary shares \| $		$ 5,000,000
Proceeds from registered direct offerings, net of transaction costs \| $																			$ 16,909,000	$ 12,814,000
Aggregate principal amount of exchangeable notes \| $																						$ 40,691,000
Accrued and unpaid interest \| $																						$ 3,071,000
Warrants to purchase ordinary share, exercise price \| $ / shares		$ 0.01
Undesignated preferred shares, par value \| $ / shares	$ 0.01																	$ 0.01	$ 0.01		$ 0.01		$ 0.01	$ 0.01		$ 0.01
Undesignated preferred shares, authorized	100,000,000																	100,000,000	100,000,000		100,000,000		100,000,000	100,000,000		100,000,000
Undesignated preferred shares issued	0																	0	0		0		0	0		0
Sales Agreement With H.C. Wainwright
Class Of Stock [Line Items]
Ordinary shares, par value \| $ / shares							$ 0.01
Number of ordinary shares sold																		6,860,532
Offering price per ordinary share \| $ / shares	$ 0.79																	$ 0.79	$ 0.79		$ 0.79		$ 0.79	$ 0.79
Proceeds from registered direct offerings, net of transaction costs \| $																		$ 5,417,000
Maximum \| Sales Agreement With H.C. Wainwright
Class Of Stock [Line Items]
May offer and sell ordinary shares for aggregate gross sales proceeds \| $							$ 16,000,000
May offer and sell ordinary shares for additional aggregate offering price \| $					$ 25,000,000
Loan and Security Agreement \| Silicon Valley Bank (SVB)
Class Of Stock [Line Items]
Loan and security agreement entered date																			Apr. 27, 2018
Maximum amount available under agreement \| $																$ 30,000,000
Long-Term Line of Credit \| $																$ 15,000,000
2024 Rights Offering
Class Of Stock [Line Items]
Subscription price per whole unit \| $ / shares						$ 1.21
Aggregate gross proceeds from rights offering \| $						$ 7,408,000
Aggregate net proceeds from rights offering \| $						$ 5,430,000
Number of units sold						6,121,965
Warrants to purchase ordinary share, exercise price \| $ / shares						$ 1.21
Private Placement \| Securities Purchase Agreement
Class Of Stock [Line Items]
Number of warrants to purchase ordinary shares														13,868
Warrants to purchase ordinary share, exercise price \| $ / shares														$ 31.5465	$ 24.3
Warrants expiry date														Jun. 03, 2025	Dec. 05, 2025
Warrants exercisable date														Jun. 03, 2020
Percentage of ordinary shares issued to purchase warrants														7.00%
Warrants exercised	0																	0	0		0		0	0
Private Placement \| Securities Purchase Agreement \| Maximum
Class Of Stock [Line Items]
Number of warrants to purchase ordinary shares															99,057
Private Placement \| June 30 SPA
Class Of Stock [Line Items]
Number of warrants to purchase ordinary shares													15,739
Warrants to purchase ordinary share, exercise price \| $ / shares													$ 27.7965				$ 21.3
Warrants expiry date	Jun. 30, 2025																Jan. 02, 2026
Percentage of ordinary shares issued to purchase warrants													7.00%
Proceeds from exercise of warrants related to registered direct offering \| $																								$ 1,796,000
Warrants exercised	84,317																	84,317	84,317		84,317		84,317	84,317	0
Private Placement \| June 30 SPA \| Maximum
Class Of Stock [Line Items]
Number of warrants to purchase ordinary shares																	112,422
October Offering
Class Of Stock [Line Items]
Proceeds from registered direct offerings, net of transaction costs \| $																			$ 13,885,000
Number of warrants to purchase ordinary shares											125,641
Number of warrants exercised for ordinary shares	1,392,701																	1,392,701	1,392,701		1,392,701		1,392,701	1,392,701
Warrants to purchase ordinary share, exercise price \| $ / shares											$ 12.1875	$ 9.75
Warrants expiry date											Oct. 22, 2025	Oct. 27, 2025
Percentage of ordinary shares issued to purchase warrants											7.00%
October Offering \| Maximum
Class Of Stock [Line Items]
Number of warrants to purchase ordinary shares												1,346,153
February Underwritten Offering
Class Of Stock [Line Items]
Offering closing date									Feb. 10, 2021	Feb. 08, 2021
Additional ordinary shares that can be purchased by underwriter									347,826
Number of warrants exercised for ordinary shares	25,333																	25,333	25,333		25,333		25,333	25,333
Warrants to purchase ordinary share, exercise price \| $ / shares									$ 21.5625	$ 21.5625
Warrants expiry date									Feb. 03, 2026	Feb. 03, 2026
Percentage of ordinary shares issued to purchase warrants									7.00%	7.00%
Proceeds from warrants connected to registered direct offerings \| $																							$ 546,000
February Underwritten Offering \| Maximum
Class Of Stock [Line Items]
Number of warrants to purchase ordinary shares									24,347	162,318
February Registered Direct Offering
Class Of Stock [Line Items]
Offering closing date								Feb. 12, 2021
Number of warrants to purchase ordinary shares								81,666
Warrants to purchase ordinary share, exercise price \| $ / shares								$ 37.5
Warrants expiry date								Feb. 09, 2026
Percentage of ordinary shares issued to purchase warrants								7.00%
Warrants to Purchase 19,890 Ordinary Shares \| Silicon Valley Bank and Life Sciences Fund II LLC
Class Of Stock [Line Items]
Warrants expiry date																Apr. 27, 2028
1-Year Warrant \| 2024 Rights Offering
Class Of Stock [Line Items]
Number of shares that can be purchased with each warrant						0.5
Proceeds from registered direct offerings, net of transaction costs \| $																					$ 1,040,000
Number of warrants to purchase ordinary shares						3,060,982
Warrants to purchase ordinary share, exercise price \| $ / shares	$ 1.21																	$ 1.21	$ 1.21		$ 1.21		$ 1.21	$ 1.21
Warrants exercised	859,825																	859,825	859,825		859,825		859,825	859,825
5-Year Warrants \| 2024 Rights Offering
Class Of Stock [Line Items]
Proceeds from registered direct offerings, net of transaction costs \| $																					$ 804,000
Number of warrants to purchase ordinary shares						6,121,965
Warrants to purchase ordinary share, exercise price \| $ / shares	$ 1.21					$ 1.21												$ 1.21	$ 1.21		$ 1.21		$ 1.21	$ 1.21
Warrants exercised	664,802																	664,802	664,802		664,802		664,802	664,802
Series B Convertible Preferred Shares \| Silicon Valley Bank and Life Sciences Fund II LLC
Class Of Stock [Line Items]
Number of warrants to purchase ordinary shares																19,890
Warrants to purchase ordinary share, exercise price \| $ / shares																$ 282.75
Undesignated Preferred Shares
Class Of Stock [Line Items]
Undesignated preferred shares, par value \| $ / shares	$ 0.01																	$ 0.01	$ 0.01		$ 0.01		$ 0.01	$ 0.01
Undesignated preferred shares, authorized	100,000,000																	100,000,000	100,000,000		100,000,000		100,000,000	100,000,000
Designated Preferred Shares
Class Of Stock [Line Items]
Undesignated preferred shares issued	0																	0	0		0		0	0
Ordinary Shares \| Silicon Valley Bank and Life Sciences Fund II LLC
Class Of Stock [Line Items]
Number of warrants to purchase ordinary shares																1,326
Exchangeable Notes
Class Of Stock [Line Items]
Ordinary shares, shares issued	3,760,155			3,760,155														3,760,155	3,760,155		3,760,155	3,760,155	3,760,155	3,760,155
Aggregate principal amount of exchangeable notes \| $				$ 11,117,000																		$ 40,691,000
Accrued and unpaid interest \| $																						3,071,000
Accrued interest \| $				$ 3,628,000																		3,628,000
Exchangeable Notes \| Private Placement
Class Of Stock [Line Items]
Aggregate principal amount of exchangeable notes \| $																						$ 40,691,000